Opportunities and challenges in the development of experimental drug combinations for cancer

Rachel W. Humphrey, Laura M. Brockway-Lunardi, David T. Bonk, Kathleen M. Dohoney, James H. Doroshow, Sandra J. Meech, Mark J. Ratain, Suzanne Topalian, Andrew Mark Pardoll

Research output: Contribution to journalArticle

Abstract

It is becoming increasingly evident that cancers are dependent on a number of altered molecular pathways and can develop diverse mechanisms of resistance to therapy with single agents. Therefore, combination regimens may provide the best hope for effective therapies with durable effects. Despite preclinical data to support this notion, there are many challenges to the development of targeted combinations including scientific, economic, legal, and regulatory barriers. A discussion of these challenges and identification of models and best practices are presented with intent of aiding the research community in addressing real and perceived barriers to the development of combination therapies for cancer.

Original languageEnglish (US)
Pages (from-to)1222-1226
Number of pages5
JournalJournal of the National Cancer Institute
Volume103
Issue number16
DOIs
StatePublished - Aug 17 2011

Fingerprint

Drug Combinations
Neoplasms
Practice Guidelines
Therapeutics
Economics
Research

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Humphrey, R. W., Brockway-Lunardi, L. M., Bonk, D. T., Dohoney, K. M., Doroshow, J. H., Meech, S. J., ... Pardoll, A. M. (2011). Opportunities and challenges in the development of experimental drug combinations for cancer. Journal of the National Cancer Institute, 103(16), 1222-1226. https://doi.org/10.1093/jnci/djr246

Opportunities and challenges in the development of experimental drug combinations for cancer. / Humphrey, Rachel W.; Brockway-Lunardi, Laura M.; Bonk, David T.; Dohoney, Kathleen M.; Doroshow, James H.; Meech, Sandra J.; Ratain, Mark J.; Topalian, Suzanne; Pardoll, Andrew Mark.

In: Journal of the National Cancer Institute, Vol. 103, No. 16, 17.08.2011, p. 1222-1226.

Research output: Contribution to journalArticle

Humphrey, RW, Brockway-Lunardi, LM, Bonk, DT, Dohoney, KM, Doroshow, JH, Meech, SJ, Ratain, MJ, Topalian, S & Pardoll, AM 2011, 'Opportunities and challenges in the development of experimental drug combinations for cancer', Journal of the National Cancer Institute, vol. 103, no. 16, pp. 1222-1226. https://doi.org/10.1093/jnci/djr246
Humphrey RW, Brockway-Lunardi LM, Bonk DT, Dohoney KM, Doroshow JH, Meech SJ et al. Opportunities and challenges in the development of experimental drug combinations for cancer. Journal of the National Cancer Institute. 2011 Aug 17;103(16):1222-1226. https://doi.org/10.1093/jnci/djr246
Humphrey, Rachel W. ; Brockway-Lunardi, Laura M. ; Bonk, David T. ; Dohoney, Kathleen M. ; Doroshow, James H. ; Meech, Sandra J. ; Ratain, Mark J. ; Topalian, Suzanne ; Pardoll, Andrew Mark. / Opportunities and challenges in the development of experimental drug combinations for cancer. In: Journal of the National Cancer Institute. 2011 ; Vol. 103, No. 16. pp. 1222-1226.
@article{2e13f3c11e8340cabb5b0ac43ab24bca,
title = "Opportunities and challenges in the development of experimental drug combinations for cancer",
abstract = "It is becoming increasingly evident that cancers are dependent on a number of altered molecular pathways and can develop diverse mechanisms of resistance to therapy with single agents. Therefore, combination regimens may provide the best hope for effective therapies with durable effects. Despite preclinical data to support this notion, there are many challenges to the development of targeted combinations including scientific, economic, legal, and regulatory barriers. A discussion of these challenges and identification of models and best practices are presented with intent of aiding the research community in addressing real and perceived barriers to the development of combination therapies for cancer.",
author = "Humphrey, {Rachel W.} and Brockway-Lunardi, {Laura M.} and Bonk, {David T.} and Dohoney, {Kathleen M.} and Doroshow, {James H.} and Meech, {Sandra J.} and Ratain, {Mark J.} and Suzanne Topalian and Pardoll, {Andrew Mark}",
year = "2011",
month = "8",
day = "17",
doi = "10.1093/jnci/djr246",
language = "English (US)",
volume = "103",
pages = "1222--1226",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "16",

}

TY - JOUR

T1 - Opportunities and challenges in the development of experimental drug combinations for cancer

AU - Humphrey, Rachel W.

AU - Brockway-Lunardi, Laura M.

AU - Bonk, David T.

AU - Dohoney, Kathleen M.

AU - Doroshow, James H.

AU - Meech, Sandra J.

AU - Ratain, Mark J.

AU - Topalian, Suzanne

AU - Pardoll, Andrew Mark

PY - 2011/8/17

Y1 - 2011/8/17

N2 - It is becoming increasingly evident that cancers are dependent on a number of altered molecular pathways and can develop diverse mechanisms of resistance to therapy with single agents. Therefore, combination regimens may provide the best hope for effective therapies with durable effects. Despite preclinical data to support this notion, there are many challenges to the development of targeted combinations including scientific, economic, legal, and regulatory barriers. A discussion of these challenges and identification of models and best practices are presented with intent of aiding the research community in addressing real and perceived barriers to the development of combination therapies for cancer.

AB - It is becoming increasingly evident that cancers are dependent on a number of altered molecular pathways and can develop diverse mechanisms of resistance to therapy with single agents. Therefore, combination regimens may provide the best hope for effective therapies with durable effects. Despite preclinical data to support this notion, there are many challenges to the development of targeted combinations including scientific, economic, legal, and regulatory barriers. A discussion of these challenges and identification of models and best practices are presented with intent of aiding the research community in addressing real and perceived barriers to the development of combination therapies for cancer.

UR - http://www.scopus.com/inward/record.url?scp=80051954603&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051954603&partnerID=8YFLogxK

U2 - 10.1093/jnci/djr246

DO - 10.1093/jnci/djr246

M3 - Article

C2 - 21765011

AN - SCOPUS:80051954603

VL - 103

SP - 1222

EP - 1226

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 16

ER -